PLA Code Application Deadline: What Labs Must Submit by September 8
Short answer: The AMA's next Proprietary Laboratory Analyses (PLA) code deadline is September 8, 2026. Labs or IVD manufacturers that miss it wait until the next cycle, delaying Medicare and payer recognition by months — and even an approved code still needs separate CLFS pricing before a claim gets paid.
What Just Changed
The American Medical Association's CPT Editorial Panel runs PLA code applications on a fixed quarterly cycle, and the Fall 2026 window closes soon. Per the AMA's own PLA Editorial Panel calendar, the application submission deadline is September 8, 2026, followed by a public agenda posting on October 13, an Editorial Panel vote on November 4, and publication of new and deleted codes on January 1, 2027 — codes that will appear in the CPT 2028 code book. A lab or manufacturer that misses September 8 does not simply wait a few weeks; it drops into the following cycle, pushing recognition of its test out by roughly another quarter.
There's also a platform change to account for. Since December 11, 2025, all PLA applications must go through the CPT Smart App rather than the legacy PLA Platform, which stopped accepting access entirely on January 13, 2026. Draft applications did not migrate — anyone who started a submission on the old system has to rebuild it from scratch, with a new Smart App profile and a signed license agreement on first login.
What a PLA Code Actually Is
PLA codes were created under a CMS final rule dated June 17, 2016 to give clinical laboratory tests a specific, trackable CPT identifier when no Category I code fits — the situation most branded molecular, genomic, and companion-diagnostic assays are in. Per AMA's PLA code guidance, only two parties may apply: the CLIA-certified or accredited laboratory actually performing the test, or the manufacturer of an FDA-approved, cleared, or classified in vitro diagnostic. An individual ordering provider cannot submit an application. The test also has to already be commercially available for use on human specimens by the time the application goes in, and the submission must include a Standard Operating Procedure describing the full test methodology.
This is a coding designation, not a coverage or payment decision. A molecular director evaluating whether to pursue a PLA code for a proprietary assay is really answering two separate questions: does this test need its own identifier to be billed and tracked accurately, and is the lab prepared for the parallel MolDX Z-code and Medicare LCD/NCD coverage work that determines whether that code actually gets paid.
Inside the Cycle Just Ahead of This One
The volume moving through this pipeline is a useful gauge of how much of the molecular testing market is actively coding new assays. The public agenda for the cycle immediately preceding the Fall 2026 deadline — applications the Editorial Panel voted on August 4, 2026, for an October 1, 2026 publication date — carried 41 pending PLA applications, per the AMA's published August 2026 PLA public agenda. Oncology assays accounted for 25 of the 41, ranging from melanoma and pancreatic-cancer profiling to minimal-residual-disease and multiple-myeloma monitoring tests. Infectious-disease assays made up another 10, including tick-borne relapsing fever, malaria, sepsis-risk, and urinary tract infection panels. The remaining six covered reproductive and genetic testing — including rapid whole genome sequencing — plus a handful of other specialties.
For comparison, the prior quarterly batch actually published — the Winter 2026 cycle — added 29 new PLA codes (0631U–0659U) alongside two revisions and four deletions, effective July 1, 2026, according to coverage of the AMA's quarterly CPT update. Application volume has been trending up quarter over quarter, which matters for lab strategy: if a comparable or competing assay class is filing for its own code, waiting too long to differentiate a proprietary test can mean entering a crowded coding lane instead of an open one.
A Code Is Not a Payment: The Gapfill Reality
Getting a PLA code assigned solves an identification problem, not a reimbursement one. Once a new code publishes, CMS still has to set a Medicare payment rate for it under the Clinical Laboratory Fee Schedule (CLFS) — either by crosswalking it to an existing comparable code or, more often for a genuinely novel assay, by running it through the gapfill process, in which each Medicare Administrative Contractor proposes a local price before CMS finalizes a national rate. CMS released its 2026 Preliminary CLFS Gapfill Determinations in a batch that will be implemented on the CY 2027 CLFS, underscoring how the pricing timeline for a brand-new code runs a full year or more behind the coding timeline. Labs that assume a published PLA code will start generating clean Medicare payments immediately are the same labs that show up later in denial and underpayment reviews — a pattern this site has covered in detail in our CLFS 2027 PAMA rate-cut breakdown and our look at why genetic testing claims get denied.
What Labs and RCM Teams Should Do Now
With roughly a week and a half left before the September 8 deadline, a molecular director or lab operations lead weighing whether to file should move through a short checklist rather than starting from scratch under pressure. First, confirm the applicant status: only the performing CLIA lab or the IVD manufacturer of record can submit, so identify who that is now if the test has changed hands or added a manufacturing partner. Second, verify commercial availability — the test must already be offered on human specimens, not still in validation, at the time of filing. Third, have the Standard Operating Procedure drafted and reviewed, since it has to describe the full test methodology in the application itself. Fourth, set up (or confirm) a CPT Smart App profile well before the deadline, since first-time users must sign a license agreement and old PLA Platform drafts cannot be carried over. Fifth, and often skipped, start the parallel MolDX registration and technical assessment conversation early rather than after the code publishes — a Z-code and Medicare LCD alignment process can run in parallel with, but is not resolved by, the PLA application itself.
Missing September 8 is not a crisis — the Winter 2027 cycle follows on a predictable schedule — but it does mean planning revenue-cycle expectations around an April 2027 publication instead of a January 2027 one, a three-month gap that can matter for a lab counting on a distinct billing identifier to support a payer contract or a coverage determination request already in motion.
Frequently Asked Questions
What is a PLA code and why would a lab want one?
A Proprietary Laboratory Analyses code is a CPT identifier created for a specific branded lab test when no existing Category I code describes it. Labs pursue one to bill and track a proprietary molecular or genomic assay with precision, rather than reporting it under a generic or unlisted code that payers scrutinize more heavily.
Who is allowed to apply for a PLA code?
Only two applicant types are accepted: the CLIA-certified or accredited clinical laboratory that actually performs the test, or the manufacturer of an FDA-approved, cleared, or classified in vitro diagnostic device. An ordering physician or an unaffiliated third party cannot submit a PLA application on a lab's behalf.
What happens if a lab misses the September 8 deadline?
The application simply moves to the next quarterly cycle rather than being rejected outright. Based on the AMA's published calendar pattern, that would push the earliest possible publication from January 1, 2027 to roughly April 2027 — a delay that can matter for payer contracting timelines already underway.
Does a new PLA code mean Medicare will pay for the test?
No. A PLA code only creates a billing identifier. CMS separately prices the code under the CLFS through crosswalking or the gapfill process, and that pricing timeline typically runs a year or more behind the code's publication date, so payment readiness has to be planned separately from the coding application.
How does a PLA code relate to a MolDX Z-code?
They serve different functions and usually run in parallel rather than sequentially. The PLA code is the AMA's CPT-level billing identifier; the Z-code is Palmetto GBA's MolDX registry identifier used by Medicare and many commercial payers to confirm a test's technical validity before applying coverage policy — a lab generally needs to pursue both processes for full reimbursement readiness.
This article is provided for general clinical and revenue-cycle decision support and does not constitute legal, coding, reimbursement, or regulatory advice. Coding and coverage requirements change frequently and vary by payer and jurisdiction; laboratories should confirm current requirements directly with the AMA, CMS, and their Medicare Administrative Contractor, and consult qualified coding or legal counsel before making billing decisions.
Sources: American Medical Association, PLA Editorial Panel meetings & calendar; American Medical Association, CPT® PLA Codes; American Medical Association, PLA Submission Platform to CPT Smart App Transition notice; American Medical Association, August 2026 CPT PLA public agenda; AAPC Knowledge Center, "AMA Posts PLA Code Update"; XiFin, "2026 Preliminary Clinical Laboratory Fee Schedule (CLFS) Gapfill Determinations"; Centers for Medicare & Medicaid Services, Clinical Laboratory Fee Schedule (CLFS) program materials.